MRI-US融合画像ガイド下前立腺生検における癌検出率の検討

DOI HANDLE Web Site オープンアクセス

書誌事項

タイトル別名
  • Early Experience with MRI-Ultrasound Fusion-Guided Prostate Biopsy in Our Institution
  • MRI-US ユウゴウ ガゾウ ガイド カ ゼンリツセンセイケン ニ オケル ガン ケンシュツリツ ノ ケントウ

この論文をさがす

抄録

A total of 100 patients were retrospectively analyzed with magnetic resonance imaging-ultrasonography (MRI-US) fusion biopsy(KOELIS, TRINITY®) at our institution between October 2019 and May 2020. The median patient age was 71 years, median prostate specific antigen (PSA) level was 7.4 ng/ml, and median PSA-density was 0.183 mg/ml. Sixty-one of the patients were positive for cancer ; 14 of them were positive by targeted biopsy only, 9 were positive by systematic biopsy only, and 38 were positive by both. Clinically significant prostate cancer (CPSC ; Gleason Score ≥3＋4 and % core ≥50%) was detected by target biopsies in 46 patients and by systematic biopsies in 33 patients. The positive core detection rate for CSPC was 32.5% for targeted biopsies and 7.0% for systematic biopsies(P＜0.0001), with a significantly higher rate for targeted biopsies. These results indicate that in MRI-US fusion biopsy, targeted biopsy has a higher detection rate for cancer and a significantly higher detection rate for clinically significant prostate cancer compared with systematic biopsy.

収録刊行物

  • 泌尿器科紀要

    泌尿器科紀要 68 (9), 291-294, 2022-09-30

    泌尿器科紀要刊行会

キーワード

詳細情報 詳細情報について

問題の指摘

ページトップへ